BridgeBio Pharma Inc

Research BridgeBio Pharma Inc (BBIO) on Bullrun: market cap USD 14.10B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBBIO
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 14.10B
• Financial periodFY2025
• RevenueUSD 502.08M
• Revenue growth126.3%
• Net income-USD 732.94M
• Free cash flow-USD 447.01M
• Gross margin95.8%

Valuation Snapshot

latest market cap is USD 14.10B.

About BridgeBio Pharma Inc

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name;

Frequently asked questions

What is BridgeBio Pharma Inc's market cap?

BridgeBio Pharma Inc's market capitalization is USD 14.10B.

What does BridgeBio Pharma Inc do?

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.